Having trouble accessing articles? Reset your cache.

Lonza to buy Cambrex units

CBM will sell its research bioproducts and microbial biopharma businesses to Lonza (SWX:LONN) for $460 million

Read the full 165 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE